Fifth Third Bancorp
SMMT icon

Fifth Third Bancorp’s Summit Therapeutics SMMT Stock Holding History

Fifth Third Bancorp’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.8K Buy
5,062
+1,330
+36% +$23.6K ﹤0.01% 3082
2026
Q1 		$70.8K Buy
3,732
+732
+24% +$11.8K ﹤0.01% 3056
2025
Q4 		$52.5K Hold
3,000
– – ﹤0.01% 1445
2025
Q3 		$62K Hold
3,000
– – ﹤0.01% 1407
2025
Q2 		$63.8K Hold
3,000
– – ﹤0.01% 1319
2025
Q1 		$57.9K Buy
3,000
+2,800
+1,400% +$56.2K ﹤0.01% 1342
2024
Q4 		$3.57K Hold
200
– – ﹤0.01% 2229
2024
Q3 		$4.38K Buy
+200
New +$2.8K ﹤0.01% 2214

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Fifth Third Bancorp's SMMT Position: Q2 2026 in Review

Fifth Third Bancorp increased its Summit Therapeutics (SMMT) stake by 36% in Q2 2026, buying an estimated $23.6K and bringing the position to 5,062 shares worth $73.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Fifth Third Bancorp first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Fifth Third Bancorp held 5,062 shares of Summit Therapeutics worth $73.8K as of Q2 2026.
  • Fifth Third Bancorp bought 1,330 Summit Therapeutics shares in Q2 2026, an estimated $23.6K.
  • Summit Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3082 holding.
  • Fifth Third Bancorp first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.